193 related articles for article (PubMed ID: 22622149)
1. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
Tsushima T; Taguri M; Honma Y; Takahashi H; Ueda S; Nishina T; Kawai H; Kato S; Suenaga M; Tamura F; Morita S; Boku N
Oncologist; 2012; 17(9):1163-70. PubMed ID: 22622149
[TBL] [Abstract][Full Text] [Related]
2. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Takayoshi K; Kusaba H; Uenomachi M; Mitsugi K; Makiyama C; Makiyama A; Uchino K; Shirakawa T; Shibata Y; Shinohara Y; Inadomi K; Tsuchihashi K; Arita S; Ariyama H; Esaki T; Akashi K; Baba E
Cancer Chemother Pharmacol; 2017 Aug; 80(2):333-342. PubMed ID: 28653251
[TBL] [Abstract][Full Text] [Related]
3. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
McWilliams RR; Foster NR; Mahoney MR; Smyrk TC; Murray JA; Ames MM; Horvath LE; Schneider DJ; Hobday TJ; Jatoi A; Meyers JP; Goetz MP
Cancer; 2017 Sep; 123(18):3494-3501. PubMed ID: 28493308
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.
Horimatsu T; Nakayama N; Moriwaki T; Hirashima Y; Fujita M; Asayama M; Moriyama I; Nakashima K; Baba E; Kitamura H; Tamura T; Hosokawa A; Yoshimura K; Muto M
Int J Clin Oncol; 2017 Oct; 22(5):905-912. PubMed ID: 28536826
[TBL] [Abstract][Full Text] [Related]
5. A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma.
Makino S; Takahashi H; Haraguchi N; Nishimura J; Hata T; Matsuda C; Ikenaga M; Murata K; Yamamoto H; Doki Y; Mori M; Mizushima T
Anticancer Res; 2017 Mar; 37(3):1495-1500. PubMed ID: 28314324
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Zaanan A; Costes L; Gauthier M; Malka D; Locher C; Mitry E; Tougeron D; Lecomte T; Gornet JM; Sobhani I; Moulin V; Afchain P; Taïeb J; Bonnetain F; Aparicio T
Ann Oncol; 2010 Sep; 21(9):1786-1793. PubMed ID: 20223786
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy in advanced small bowel adenocarcinoma.
Locher C; Malka D; Boige V; Lebray P; Elias D; Lasser P; Ducreux M
Oncology; 2005; 69(4):290-4. PubMed ID: 16282708
[TBL] [Abstract][Full Text] [Related]
9. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Popov I; Milicević M; Radosević-Jelić Lj
Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
[TBL] [Abstract][Full Text] [Related]
10. Treatment of peritoneal metastases from small bowel adenocarcinoma.
Rovers KP; de Bree E; Yonemura Y; de Hingh IH
Int J Hyperthermia; 2017 Aug; 33(5):571-578. PubMed ID: 27919181
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study.
Nishikawa Y; Horimatsu T; Oka S; Yamada T; Mitsui K; Yamamoto H; Takahashi K; Shiomi A; Hotta K; Takeuchi Y; Kuwai T; Ishida F; Kudo SE; Saito S; Ueno M; Sunami E; Yamano T; Itabashi M; Ohtsuka K; Kinugasa Y; Matsumoto T; Sugai T; Uraoka T; Kurahara K; Yamaguchi S; Kato T; Okajima M; Kashida H; Fujita F; Ikematsu H; Ito M; Esaki M; Kawai M; Yao T; Hamada M; Koda K; Fukai Y; Komori K; Saitoh Y; Kanemitsu Y; Takamaru H; Yamada K; Nozawa H; Takayama T; Togashi K; Shinto E; Torisu T; Toyoshima A; Ohmiya N; Kato T; Otsuji E; Nagata S; Hashiguchi Y; Sugihara K; Ajioka Y; Tanaka S
JCO Glob Oncol; 2024 Feb; 10():e2300392. PubMed ID: 38330276
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Suenaga M; Mizunuma N; Chin K; Matsusaka S; Shinozaki E; Oya M; Ueno M; Yamaguchi T; Muto T; Konishi F; Hatake K
Surg Today; 2009; 39(1):27-31. PubMed ID: 19132464
[TBL] [Abstract][Full Text] [Related]
13. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Legué LM; van Erning FN; Bernards N; Lemmens VEPP; de Hingh IHJT; Creemers GJ
Target Oncol; 2019 Dec; 14(6):699-705. PubMed ID: 31625001
[TBL] [Abstract][Full Text] [Related]
14. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
Zaanan A; Gauthier M; Malka D; Locher C; Gornet JM; Thirot-Bidault A; Tougeron D; Taïeb J; Bonnetain F; Aparicio T;
Cancer; 2011 Apr; 117(7):1422-8. PubMed ID: 21425142
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery.
Uemura M; Qiao W; Fournier K; Morris J; Mansfield P; Eng C; Royal RE; Wolff RA; Raghav K; Mann GN; Overman MJ
BMC Cancer; 2017 May; 17(1):331. PubMed ID: 28506255
[TBL] [Abstract][Full Text] [Related]
16. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
17. Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis.
Nakazawa T; Narita Y; Kumanishi R; Ogata T; Matsubara Y; Nozawa K; Kato K; Honda K; Masuishi T; Bando H; Kadowaki S; Ando M; Hara K; Tajika M; Muro K
Anticancer Res; 2021 Oct; 41(10):5147-5155. PubMed ID: 34593466
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and treatment outcomes of metastatic or locally unresectable small bowel adenocarcinoma.
Li X; Ying H; Cheng Y; Zhao L; Zhao S; Bai C; Zhou J
J BUON; 2019; 24(6):2539-2545. PubMed ID: 31983130
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
Ono M; Shirao K; Takashima A; Morizane C; Okita N; Takahari D; Hirashima Y; Eguchi-Nakajima T; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Gastric Cancer; 2008; 11(4):201-5. PubMed ID: 19132481
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
